Facebook
Twitter
LinkedIn
ForwardNCCN 2024 Oncology Fellows Program: New Horizons in Quality Cancer Care
Designed specifically for oncology fellows, this half-day, CE-certified program seeks to educate future oncology practitioners about the application of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the importance of communicating with patients and caregivers about difficult and sensitive topics, and preparing for entry into the oncology workforce.
Target Audience
This program is designed to meet the educational needs of second- and third-year medical, surgical, and radiation oncology fellows.
Learning Objectives
The goal of this activity is to ensure that oncology fellows, as members of the interprofessional oncology care team, have the knowledge and skills necessary to apply the standards of care to their practice and health care setting for patients with cancer.
Following this program, participants should be able to:
Global Learning Objectives
• Evaluate advances in the treatment of patients with cancer and key updates in the NCCN Guidelines® and apply appropriate treatment and supportive care strategies to optimize patient education and care.
• Review issues related to the following topics: Health-Related Social Needs: How to Identify and Address the Needs of Your Patients; Health Insurance 101: Helping Patients Navigate the Health Insurance Maze; Difficult Conversations: How to Communicate with Patients and Caregivers; Team-Based Management of Immunotherapy-Related Toxicities; and Preparing to Launch: What You Need to Know (but no one ever told you) about Entering the Oncology Workforce.
Health-Related Social Needs: How to Identify and Address the Needs of Your Patients
• Review the core measures of health-related social needs (HRSN).
• Discuss how and when to screen patients for HRSN, barriers to screening, and how to discuss HRSN with patients and caregivers.
• Describe the roles of other oncology care team members in addressing HRSN and the importance of educating patients and caregivers about these roles prior to referral.
Health Insurance 101: Helping Patients Navigate the Health Insurance Maze
• Describe different insurance types and how coverage can affect patients with cancer and the treatment they receive.
• Discuss potential insurance-related barriers and how to address them.
• Identify advocacy organizations and members of the interprofessional oncology care team that help patients navigate health insurance issues.
Difficult Conversations: How to Communicate with Patients and Caregivers
• Explain the importance of having difficult conversations with patients and caregivers and how these types of conversations can impact patient care.
• Describe the differences between palliative, supportive, and hospice care and how to communicate with patients and caregivers about them.
• Discuss resources that are available to patients and caregivers to help guide them in making difficult treatment decisions.
Team-Based Management of Immunotherapy-Related Toxicities
• Describe the different classes of immunotherapies used for cancer treatment.
• Recognize the toxicities that may occur with cancer immunotherapies.
• Discuss multidisciplinary strategies to facilitate early diagnosis and treatment of immunotherapy-related toxicities.
Preparing to Launch: What You Need to Know (but no one ever told you) about Entering the Oncology Workforce
• Incorporate practical skills that can be used to enhance career development and progression.
• Describe common obstacles and pitfalls that may be faced in early career.
• Explain key factors that will support a successful transition from fellow to attending physician.
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty, Moderator, and Planner Disclosures
The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.
Cynthia S. Anderson, MD
Karen Costello, MSS, LSW, OSW-C
Deborah Freedman-Cass
Heather Jones, PharmD, MS
Karen Kanefield
Wui-Jin Koh, MD
Kimberley Lee, MD, MHS
Bryan Loy, MD, MBA
Randall A. Oyer, MD
Kavitha Ramchandran, MD
Carey Ramirez, ANP-C, ACHPN
Namrata Singh, MD, MSCI
John W. Sweetenham, MD
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Eucharia Borden, MSW, LCSW, OSW-C, FAOSW
BeiGene: Honoraria
Carmen E. Guerra, MD, MSCE
Genentech, Inc.: Grant/Research Support
Guardant Health: Scientific Advisor
Wenora Johnson
Flatiron Health, Inc.: Consulting Fee
GSK: Honoraria
Xilio Therapeutics: Honoraria
Benjamin H. Kaffenberger, MD, MS
ADC Therapeutics: Consulting Fee
Biogen Idec: Consulting Fee; Grant Research Support
InflaRx: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Consulting Fee
Timothy Kubal, MD, MBA
Apellis Pharmaceuticals: Scientific Advisor
Anthony J. Olszanski, MD, RPh
Bristol Myers Squibb: Scientific Advisor
InstilBio: Scientific Advisor
Merck & Co., Inc.: Scientific advisor
Novartis Pharmaceuticals Corporation: Scientific Advisor
Oncosec Immunotherapies: Scientific Advisor
Pfizer Inc.: Honoraria
Replimune: Scientific Advisor
John A. Thompson, MD
Alpine Immune Sciences: Equity Interest/Stock Options
Mabquest SA: Scientific Advisor
NCCN Staff Disclosures
The planners listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Crystal Denlinger, MD, FACP
2seventy bio: Grant/Research Support
AbbVie, Inc.: Grant/Research Support
Bluebird bio: Grant/Research Support
Bristol Myers Squibb: Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Genentech, Inc: Grant/Research Support
GSK: Grant/Research Support
Pfizer Inc: Grant/Research Support
sanofi-aventis U.S.: Grant/Research Support
None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this live activity for a maximum of 5.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 5.50 AMA PRA Category 1 Credit™
- 5.50 Participation
Price
Please log in with the same email address used for program registration.
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing